AHAlbert Holvast

Albert Holvast

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Albert Holvast has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • A Huckriede

    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

    2 shared publications
  • Aalzen de Haan

    Department of Rheumatology and Clinical Immunology, Division of Infectious Diseases, Department of Internal Medicine, Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Laboratory for Infectious Diseases, Groningen and Solvay Pharmaceuticals, Weesp, The Netherlands

    2 shared publications
  • Abraham Palache

    Department of Rheumatology and Clinical Immunology, Division of Infectious Diseases, Department of Internal Medicine, Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Laboratory for Infectious Diseases, Groningen and Solvay Pharmaceuticals, Weesp, The Netherlands

    2 shared publications
  • Anke Huckriede

    Department of Rheumatology and Clinical Immunology, Division of Infectious Diseases, Department of Internal Medicine, Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Laboratory for Infectious Diseases, Groningen and Solvay Pharmaceuticals, Weesp, The Netherlands

    2 shared publications
  • C A Benne

    Laboratory for Infectious Diseases, Groningen, The Netherlands

    2 shared publications
  • C G M Kallenberg

    Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study

    by Albert Holvast, Sander van Assen, Aalzen de Haan, Anke Huckriede, Cornelis A. Benne, Johanna Westra, Abraham Palache, Jan Wilschut, Cees G. M. Kallenberg, Marc Bijl

    Objective. In SLE, a decreased antibody response on influenza vaccination has been reported. In this study, we assessed whether a booster vaccination could improve antibody responses, as determined by seroprotection rates, in SLE patients. Methods. SLE patients (n = 52) with quiescent disease (SLEDAI ⩽4) and healthy controls (HCs) (n = 28) received subunit influenza vaccine in October–December 2007. After 4 weeks, only SLE patients received a second dose of vaccination. Sera were obtained before both vaccinations, and 4 weeks after the second vaccination. At each visit, SLE disease activity was recorded. The haemagglutination inhibition test was used to measure antibody titres. Seroprotection was defined as a titre ⩾40. Results. Following the first vaccination, seroprotection rates and geometric mean titres (GMTs) to each vaccine strain increased in both SLE patients and controls to comparable levels. Seroprotection rates in SLE patients after the first vaccination were 86.5% to A/H1N1, 80.8% to A/H3N2 and 61.5% to the B-strain while GMTs were 92.6, 56.2 and 39.2, respectively. Overall, the booster vaccination did not lead to a further rise of seroprotection rates and GMTs in SLE patients. However, in patients not vaccinated in the previous year, GMT and seroconversion rate to A/H1N1 did rise following the booster vaccination. Both influenza vaccinations did not increase SLEDAI scores. Conclusions. Additional value of a booster influenza vaccination in SLE is limited to patients who were not vaccinated in the previous year.


  • Open Access

    Studies of cell‐mediated immune responses to influenza vaccination in systemic lupus erythematosus

    by Albert Holvast, Sander van Assen, Aalzen de Haan, Anke Huckriede, Cornelis A. Benne, Johanna Westra, Abraham Palache, Jan Wilschut, Cees G. M. Kallenberg, Marc Bijl

    Objective: Both antibody and cell‐mediated responses are involved in the defense against influenza. In patients with systemic lupus erythematosus (SLE), a decreased antibody response to subunit influenza vaccine has been demonstrated, but cell‐mediated responses have not yet been assessed. This study was therefore undertaken to assess cell‐mediated responses to influenza vaccination in patients with SLE.Methods: Fifty‐four patients with SLE and 54 healthy control subjects received subunit influenza vaccine. Peripheral blood mononuclear cells and sera were obtained before and 1 month after vaccination. Cell‐mediated responses to A/H1N1 and A/H3N2 vaccines were evaluated using an interferon‐γ (IFNγ) enzyme‐linked immunospot assay and flow cytometry. Antibody responses were measured using a hemagglutination inhibition test.Results: Prior to vaccination, patients with SLE had fewer IFNγ spot‐forming cells against A/H1N1 compared with control subjects and a lower frequency of IFNγ‐positive CD8+ T cells. After vaccination, the number of IFNγ spot‐forming cells increased in both patients and control subjects, although the number remained lower in patients. In addition, the frequencies of CD4+ T cells producing tumor necrosis factor and interleukin‐2 were lower in patients after vaccination compared with healthy control subjects. As expected for a subunit vaccine, vaccination did not induce a CD8+ T cell response. For A/H3N2‐specific responses, results were comparable. Diminished cell‐mediated responses to influenza vaccination were associated with the use of prednisone and/or azathioprine. The increase in A/H1N1‐specific and A/H3N2‐specific antibody titers after vaccination was lower in patients compared with control subjects.Conclusion: In addition to a decreased antibody response, cell‐mediated responses to influenza vaccination are diminished in patients with SLE, which may reflect the effects of the concomitant use of immunosuppressive drugs. This may render these patients more susceptible to (complicated) influenza infections.


  • Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination

    by A Holvast, C A Stegeman, C A Benne, A Huckriede, J C Wilschut, A M Palache, C G M Kallenberg, M Bijl

    Objectives: Wegener’s granulomatosis (WG) is a systemic vasculitis characterised by relapsing and remitting disease activity. Immunosuppressive drugs are used to control disease, but increase susceptibility to infection. Therefore, influenza vaccination should be considered in WG patients. This study was performed to assess the immunogenicity of influenza vaccination in WG patients. Methods: A randomised, controlled trial was performed in WG patients with quiescent disease, defined as a Birmingham vasculitis activity score (BVAS) less than 2. Patients were randomly assigned to receive influenza vaccination (n = 49) or to participate as controls (n = 23). In addition, healthy controls (n = 49) were vaccinated. At entry and at 1 and 3–4 months after entry, antibody responses to vaccination were determined. Furthermore, disease activity was measured (BVAS), adverse effects were recorded and antineutrophil cytoplasmic autoantibody (ANCA) titres were determined. Results: WG patients achieved high seroprotection rates to all three influenza strains, comparable with healthy controls. Only the A/H1N1 strain patients had a lower seroconversion rate (p = 0.002) and geometric mean titre (p = 0.037) than controls. After 1 month, one control and one vaccinated WG patient had developed active disease. At 3–4 months, two additional control patients had developed active disease compared with none of the vaccinated patients (p = 0.099). Vaccination did not influence ANCA titres. Adverse effects did not differ between patients and healthy controls. Conclusions: Influenza vaccination in WG patients with quiescent disease induced a sufficient antibody response. Trial registration number: NTR1130.


  • Open Access

    Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

    by A Holvast, A Huckriede, J Wilschut, G Horst, J J C De Vries, C A Benne, C G M Kallenberg, M Bijl

    Objective: to assess the safety and efficacy of influenza vaccination in patients with systemic lupus erythematosus (SLE), and to evaluate the influence of immunosuppressive drugs on the immune response. Methods: SLE patients (n = 56) and healthy controls (n = 18) were studied. All patients had quiescent disease (SLE disease activity index ⩽5). Four patient groups were defined on the basis of their drug use: (1) no drug treatment; (2) hydroxychloroquine treatment; (3) azathioprine treatment; (4) prednisone treatment. Participants received trivalent influenza subunit vaccine during October/November 2003. Disease activity scores and side effects were recorded. Antibody titres against influenza virus were measured before and 30 days after vaccination using the haemagglutination inhibition assay. Results: Influenza vaccination did not result in changes in disease activity and was well tolerated. SLE patients had fewer seroconversions or fourfold titre rises for A/H1N1 (pConclusions: Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls. Use of azathioprine was associated with a trend to decreased vaccination efficacy.